97 search results for: Atopic Dermatitis
The Benefits of Early Intervention in Reducing the Burden of Disease in Children With Atopic Dermatitis
This page presents educational material, infographics, and video highlights from our recent ADVENT symposia, including the 2025 World Congress of Pediatric Dermatology (WCPD) in Buenos Aires, Argentina, exploring the pathophysiology of type 2 inflammation and atopic dermatitis, the burden of disease leading to cumulative life course impairment (CLCI), and the risk of the atopic march in pediatric patients with atopic dermatitis.
The Burden of a Lifetime: Can Disease Modification Rewrite the Narrative of Atopic Dermatitis?
Professors Bouaziz, Paller, and Irvine discuss the clinical burden of atopic dermatitis, the biomarkers of subclinical control, and evidence of potential disease modification in AD at EADV 2025.
Can Therapy-Free Disease Control Be Achieved in Atopic Dermatitis?
In this soundbite video from the April 2025 ADVENT Forum in Lisbon, Portugal, Prof. Thomas Bieber discusses emerging evidence that therapy-free disease control may be possible in atopic dermatitis, citing pediatric dupilumab data showing that a subset of patients-maintained remission after treatment discontinuation.
The Burden of a Lifetime: Can Disease Modification Rewrite the Narrative of Atopic Dermatitis?
Join Professors Jean-David Bouaziz, Amy Paller, and Alan Irvine for a dynamic presentation on the multifaceted burden of atopic dermatitis, the evolving concept of disease modification, and how targeted systemic therapies may help improve long-term patient outcomes.
What Drives Chronic Itch and the Itch-Scratch Cycle in Atopic Dermatitis?
Watch this short video to learn how type 2 inflammation, skin barrier dysfunction, and neurosensitization contribute to chronic itch and the itch-scratch cycle in atopic dermatitis
Can Therapy-Free Disease Control Be Achieved in Atopic Dermatitis?
In this soundbite video from the April 2025 ADVENT Forum in Lisbon, Portugal, Prof. Amy Paller reviews a Japanese study showing that early proactive treatment of infant atopic dermatitis with topical corticosteroids reduced the incidence of food allergy but was also associated with decreased gains in height and weight.
Guideline-Based Diagnosis of Atopic Dermatitis
Explore 3 interactive patient cases to learn more about the signs, symptoms, and burden of atopic dermatitis. Diagnose the patients based on a variety of cases and presentations based on American Academy of Dermatology (AAD) criteria and assess their disease severity
How Biologic Therapy May Lead to Disease Modification in Infants and Children with Atopic Dermatitis
The underlying pathophysiology of atopic dermatitis (AD) is driven by dysregulation of type 2 immunity that contributes to skin barrier dysfunction. AD typically develops very early in life and children with AD often develop other atopic conditions such as food allergy, asthma, and allergic rhinitis in a progression called the atopic march. Early treatment may help reduce the atopic march and other comorbidities to lessen the lifetime burden created by these diseases. There may even be a window of opportunity for disease modification.
Decoding the Clinical Puzzle: Navigating Diagnostic Complexity Across Inflammatory Skin Diseases
Dr Sarina Elmariah highlights the clinical challenges in diagnosing inflammatory skin diseases, using prurigo nodularis as a case study. Drs Culton, Eichenfield, and Hawkes then join in to discuss additional challenges and complexities when diagnosing other skin diseases.
CLCI in Atopic Dermatitis Infographic
This infographic highlights how uncontrolled moderate‑to‑severe atopic dermatitis (AD) can lead to Cumulative Life Course Impairment (CLCI) by contributing to ongoing physical, psychological, and social burdens such as itch and sleep loss, impaired bone growth and mental health challenges. It emphasizes the importance of early and effective disease control to help reduce long‑term impact on patients.
Emerging Perspectives on the Disease Burden and Management of Children with Atopic Dermatitis
Join Christine Bangert, Mark Boguniewicz and Perla Lansang for an educational symposium on atopic dermatitis (AD) in children, exploring the diagnosis and pathophysiology of AD in children, the life-long effects of uncontrolled disease beyond the skin, and current and emerging therapies.
ESPD 2024 | Atopic Dermatitis in Children: Can Early Therapeutic Intervention Shape Disease Course?
This symposium illustrated the ways type 2inflammation contributes to atopic dermatitis (AD) disease pathogenesis within and beyond the skin, discussed the importance of early intervention in children with AD, and explored the potential for disease modification. The program concluded with a review of the latest clinical and real-world data on advanced systemic treatments for children with AD.
